# Semaglutide vs Sitagliptin

> **NCT05195944** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **University Health Network, Toronto** · enrollment: 58 (estimated)

## Conditions studied

- Liver Transplant; Complications
- Diabetes Mellitus
- NASH - Nonalcoholic Steatohepatitis
- NAFLD

## Interventions

- **DRUG:** Semaglutide Treatment
- **DRUG:** Sitagliptin 100mg

## Key facts

- **NCT ID:** NCT05195944
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-10-26
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05195944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05195944, "Semaglutide vs Sitagliptin". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05195944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*